{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:00:10Z","timestamp":1776106810082,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":3718,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1111\/j.1538-7836.2012.04866.x","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T11:08:40Z","timestamp":1343128120000},"page":"1979-1987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results"],"prefix":"10.1016","volume":"10","author":[{"given":"V.","family":"PENGO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"CRIPPA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"FALANGA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"FINAZZI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"MARONGIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"MOIA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"PALARETI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"POLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"TESTA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"TIRAFERRI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"TOSETTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"TRIPODI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"SIRAGUSA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"MANOTTI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0025","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","article-title":"Update on antithrombotic therapy. New anticoagulants","volume":"121","author":"Eikelboom","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta\u2010analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0045","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","article-title":"Obesity and the risk of new\u2010onset atrial fibrillation","volume":"292","author":"Wang","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0055","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long\u2010term anticoagulant therapy (RE\u2010LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0060","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE\u2010LY trial","volume":"155","author":"Oldgren","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0065","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE\u2010LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","article-title":"Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE\u2010LY (randomized evaluation of long\u2010term anticoagulation therapy) trial","volume":"125","author":"Hohnloser","year":"2012","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events. a meta\u2010analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/sim.4780080408","article-title":"How study design affects outcomes in comparisons of therapy. I: medical","volume":"8","author":"Colditz","year":"1989","journal-title":"Stat Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0085","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open\u2010label, parallel\u2010group, single\u2010centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0100","unstructured":"European Medicines Agency (EMEA). European public assessment report: Pradaxa. http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/pradaxa\/H\u2010829\u2010PI\u2010en.pdf Accessed 3 November 2009."},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0105","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim\u2019s Pradaxa available in US pharmacies starting Wednesday, November 3 [press release]. http:\/\/www.prnewswire.com\/news\u2010releases\/boehringer\u2010ingelheims\u2010pradaxa\u2010available\u2010in\u2010us\u2010pharmacies\u2010starting\u2010Wednesday\u2010November\u20103\u2010106474818.html. Accessed 1 November 2010.."},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0110","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0120","unstructured":"European Medicine Agency. Pradaxa summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000829\/WC500041059.pdf. Accessed 10 February 2012."},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0125","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/0091270011409231","article-title":"Renal profiles of anticoagulants","volume":"52","author":"Harder","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0130","series-title":"Xarelto (Rivaroxaban) Summary of Product Characteristics","year":"2009"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0135","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1160\/TH08-09-0592","article-title":"Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention","volume":"101","author":"Poli","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0145","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1160\/TH11-10-0721","article-title":"Impact of glomerular filtration estimate on bleeding risk in very old patients treated with VKA: results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics)","volume":"107","author":"Poli","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0150","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non\u2010valvular atrial fibrillation from the RE\u2010LY trial","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"ATLAS ACS 2\u2013TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0160","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"A randomized, placebo\u2010controlled, crossover study in healthy subjects reversal of rivaroxaban and dabigatran by prothrombin complex concentrate","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2012.04866.x_bb0165","unstructured":"BoehringerIngelheim Pharmaceuticals. RELY\u2010ABLE long term multi\u2010center extension of dabigatran treatment in patients with atrial fibrillation who completed RE\u2010LY trial. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00808067?term=NCT00808067&rank=1; accessed 15 January 2012."}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2012.04866.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622064868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622064868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2012.04866.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:57:41Z","timestamp":1761533861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622064868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1538783622064868"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04866.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04866.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}